Financial News Feed

Stronger Sell Today AFMD ranks #4512 as SELL CANDIDATE #4512 Weaker Sell

Affimed N.V. stock forecast

AFMD stock forecast

Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments....

Read more

AFMD earnings call for the period ending March 31, 2019....

Read more

No summary available....

Read more

Clinical stage biotech Affimed N.V. said Wednesday it is terminating its phase I program for AFM11 to focus on its innate immunity portfolio. The company had put two clinical trials of the cancer treatment on hold back in October after one patient died and two others experienced life-threatening events in the high-dose group. The trials were testing the drug in patients with types of non-Hodgkin lymphoma and acute lymphoblastic leukemia. Heidelberg, Germany-based Affimed said it will start a study of AFM13 this year and enter the clinic with AFM24. ""We strongly believe our innate cell engagers could enhance current immuno-oncology approaches and address unmet patient needs in treating hematologic and solid tumor malignancies," Chief Executive Dr. Adi Hoess said in a statement. "We have determined that the optimal use of our resources at this time is to advance our innate cell engagers, focusing their development on indications with high unmet need and the potential for a rapid path to regulatory approval." The company's Chief Scientific Officer Dr....

Read more

Affimed reports Q1 results
11:37am, Wednesday, 22'nd May 2019
No summary available....

Read more

Affirmed Therapeutics (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Read more

Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results....

Read more

Affirmed Therapeutics (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

Read more

No summary available....

Read more

In trying to determine the current valuation of Affimed N.V. (NasdaqGM:AFMD) shares, we note that the Book to Market ratio of the shares stands at 0.171766. It’s commonly accepted that a Book to Mar...

Read more

Affimed N.V. (NASDAQ:AFMD) and OncoSec Medical Incorporated (NASDAQ:ONCS) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, analyst recommendations,...

Read more

At present levels, traders are keeping a close eye on shares of Affimed N.V. (AFMD). During a recent scan, we have spotted Span A above Span B. If this position holds, traders might be anticipating a ...

Read more

Zooming in closer on shares of Affimed N.V. (AFMD), we have noted that the Plus Directional Indicator is currently above the Minus Directional Indicator. Traders following these indicators might be lo...

Read more

The Current Ratio of Affimed N.V. (NasdaqGM:AFMD) is 3.01. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all ...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank